Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine
November 11, 2023 08:31 ET
|
Novo Nordisk A/S
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity...
COMPASS Prequalification Tool launches the 2022 COMPASS Select List
December 06, 2022 11:07 ET
|
Bespoke Metrics
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- COMPASS, by Bespoke Metrics, has released its inaugural COMPASS Select List. This list recognizes the top subcontractors in the COMPASS Prequalification...
NUVERRA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of NES and Encourages Investors to Contact the Firm
December 14, 2021 12:44 ET
|
Bragar Eagel & Squire
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
Jounce Therapeutics Announces Update on Vopratelimab Program
November 02, 2020 07:00 ET
|
Jounce Therapeutics, Inc.
- No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis- - First patient dosed in SELECT trial of vopratelimab in combination with JTX-4014 in...
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
August 07, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in...
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies
February 06, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
- Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TISvopra) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit...
PRIVATE BLACK CARD COMMUNITY ‘SELECT’ LAUNCHES ALL-NEW ‘SELECT HOTELS’ BOOKING PROGRAM
September 07, 2016 08:25 ET
|
SELECT
New York, NY, Sept. 07, 2016 (GLOBE NEWSWIRE) -- SELECT, the preeminent black card and concierge service, announced the launch of their all-new SELECT HOTELS Travel Program. The first-of-its-kind...
FoodFan, Inc. Launches Exclusive Discount Program, Select
August 08, 2013 11:07 ET
|
FoodFan Inc.
NEW YORK, Aug. 8, 2013 (GLOBE NEWSWIRE) -- FoodFan Inc. - the social destination for discovering and sharing restaurants - launched Select, the first exclusive membership program that lets diners save...